Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 37

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 37
---
 vote is advisory, it is not binding on the board of directors or Repare. Nevertheless, the views expressed by the shareholders, whether through this vote or otherwise, are important to management and the board of directors and, accordingly, the board of directors and the compensation committee intend to consider the results of this vote in making determinations in the future regarding executive compensation arrangements.

<div align='center'>**OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE APPROVAL OF THE NON-BINDING ADVISORY VOTE ON EXECUTIVE COMPENSATION

25**</div>

EXECUTIVE OFFICERS The following table sets forth, for our current executive officers, their ages and position held with us as of the date of this proxy statement:

| NAME                 |     | AGE |     | POSITION(S)                                                                  |
| Steve Forte          |     |  46 |     | President, Chief Executive Officer and Chief Financial Officer, and Director |
| Sandra Alves         |     |  46 |     | Senior Vice President, Chief Accounting Officer                              |
| Michael Zinda, Ph.D. |     |  54 |     | Executive Vice President, Chief Scientific Officer                           |

Biographical information for Steve Forte is included above under the caption “Information Regarding Director Nominees and Current Directors—Directors Continuing in Office Until the 2026 Annual Meeting of Shareholders.” Sandra Alveshas served as our Senior Vice President, Chief Accounting Officer since April 2025, and previously served as our Vice President, Finance and Corporate Controller from March 2020 to April 2025. Prior to joining us, Ms. Alves served as controller at Clementia Pharmaceuticals Inc., from May 2013 to January 2020, during which time Clementia was acquired by Ipsen S.A. From June 2007 to April 2013, Ms. Alves served as controller at Thallion Pharmaceuticals Inc. until its acquisition by Bellus Health. Ms. Alves holds a B.Com. in accounting from Concordia University and is a Certified Public Accountant. Michael Zinda, Ph.D.has served as our Executive Vice President, Chief Scientific Officer since May 2019 and previously served as Executive Vice President, Head of Research and Development of our U.S. subsidiary, Repare Therapeutics USA Inc., from June 2017 to May 2019. Prior to joining us, Dr. Zinda spent 16 years at AstraZeneca from 2001 to May